198 related articles for article (PubMed ID: 9465971)
1. New monoclonal antibody approved as lymphoma therapy.
Am J Health Syst Pharm; 1998 Jan; 55(2):110. PubMed ID: 9465971
[No Abstract] [Full Text] [Related]
2. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
Kinoshita T; Nagai H; Murate T; Saito H
J Clin Oncol; 1998 Dec; 16(12):3916. PubMed ID: 9850038
[No Abstract] [Full Text] [Related]
3. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
[TBL] [Abstract][Full Text] [Related]
4. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
Hao LC; Zhang LZ
Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
[No Abstract] [Full Text] [Related]
5. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
Massengale WT; McBurney E; Gurtler J
J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
[TBL] [Abstract][Full Text] [Related]
6. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
Kollmar O; Becker S; Schilling MK; Maurer CA
Transplantation; 2002 Feb; 73(4):669-70. PubMed ID: 11889454
[No Abstract] [Full Text] [Related]
7. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
8. [Resistance to rituximab and CD20 mutation].
Terui Y; Hatake K
Nihon Rinsho; 2007 Jan; 65 Suppl 1():416-23. PubMed ID: 17474440
[No Abstract] [Full Text] [Related]
9. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B
Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
Clarke LE; Bayerl MG; Ehmann WC; Helm KF
J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with anti-CD20 compounds.
von Schilling C
Semin Cancer Biol; 2003 Jun; 13(3):211-22. PubMed ID: 12959352
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow experts are still debating the value of purging.
Benowitz S
J Natl Cancer Inst; 2000 Feb; 92(3):190-2. PubMed ID: 10655432
[No Abstract] [Full Text] [Related]
15. FMC7 is an epitope of CD20.
Deans JP; Polyak MJ
Blood; 2008 Feb; 111(4):2492; author reply 2493-4. PubMed ID: 18263793
[No Abstract] [Full Text] [Related]
16. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses.
Serke S; Schwaner I; Yordanova M; Szczepek A; Huhn D
Cytometry; 2001 Apr; 46(2):98-104. PubMed ID: 11309819
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
[No Abstract] [Full Text] [Related]
19. Use of rituximab, the new FDA-approved antibody.
Leget GA; Czuczman MS
Curr Opin Oncol; 1998 Nov; 10(6):548-51. PubMed ID: 9818234
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
